ASCO GU 2026

Encouraging new data in Prostate cancer

Combination is the way to go - but how to select?

T-Cell-Engager

Neoadjuvant therapy after molecular biopsy testing

Actinium radioligand therapy

New Mode of Action in mCRPC

Radium-223 + Enzalutamid

Benefit of PARPi + ABI combination

Patient Preferences for ARPI vs ADT in nmHSPC: A Global…

EZH2 oral molecule to enhance ARPI

PSA-dynamics in TALAPRO-2

T-cell engager - first in human

Precision medicine for prostate cancer

Post-IO in RCC: Promising Efficacy, Evolving Survival…

Early SBRT shows safety, no added benefit

Upcoming new standard for adjuvant RCC

Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab

Long‑term effects of adjuvant therapy

Advances in the Adjuvant Treatment of RCC

Real World Data - RCC

New second-line option in mRCC

New follow-up therapy with lenvatinib + belzutifan

HIF based combination are here to stay

Balancing efficacy and toxicity: the challenge in high…

Belzutifan + Lenvatinib: A New Second-Line Approach in…

Combination therapy in adjuvant RCC

Tratamiento después de la inmunoterapia en el carcinoma…

Important steps towards biomarker driven treatment of…

Closing the gap for platin eligibility

BCG plus CPI for NMIBC - do the benefits outweigh the…

New machanism of action in pts with UC

Promising data - how to stratify the patients for the…

EV+P new SOC in MIBC

pCR in MIBC under EV + P

Perioperative EV+Pembrolizumab in MIBC

ctDNA from plasma and urine in MIBC

A new class of drug in luminal UC

Rethinking the use of HER2neu in routine clinical…

MIBC - time for a historic paradigm shift?

ctDNA testing: Who, how and how often?

Perioperative EV + P - the new standard?!

New perioperative standard for MIBC

Urinary ctDNA vs. plasma ctDNA

Cáncer de vejiga músculo-invasivo: ¿es hora de un…

EV + P : nouveau standard de traitement pour le TVIM

Une nouvelle classe de médicaments pour le carcinome…